These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34125326)

  • 1. Comparison of two-year treatment outcomes between subthreshold micropulse (577 nm) laser and aflibercept for diabetic macular edema.
    Lai FHP; Chan RPS; Lai ACH; Tsang S; Woo TTY; Lam RF; Yuen CYF
    Jpn J Ophthalmol; 2021 Sep; 65(5):680-688. PubMed ID: 34125326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
    Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M
    Health Technol Assess; 2022 Dec; 26(50):1-86. PubMed ID: 36541393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aflibercept plus micropulse laser versus aflibercept monotherapy for diabetic macular edema: 1-year results of a randomized clinical trial.
    Abouhussein MA; Gomaa AR
    Int Ophthalmol; 2020 May; 40(5):1147-1154. PubMed ID: 31919773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
    Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
    JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of micropulse laser in patients with diabetic macular edema at the Department of Ophthalmology, Faculty Hospital Hradec Králové.
    Veselá Š; Hejsek L; Stepanov A; Dusová J; Marak J; Jirásková N; Studnička J
    Cesk Slov Oftalmol; 2018; 74(2):53-58. PubMed ID: 30441950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic Macular Edema and Diode Subthreshold Micropulse Laser: A Randomized Double-Masked Noninferiority Clinical Trial.
    Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M;
    Ophthalmology; 2023 Jan; 130(1):14-27. PubMed ID: 35973593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does dexamethasone implant combination with aflibercept monotherapy affect one-year outcomes in treatment-naive diabetic macular edema with inflammatory biomarkers?
    Ozsaygılı C; Bayram N
    Int Ophthalmol; 2024 Feb; 44(1):51. PubMed ID: 38336941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept with adjuvant micropulsed yellow laser versus aflibercept monotherapy in diabetic macular edema.
    Khattab AM; Hagras SM; AbdElhamid A; Torky MA; Awad EA; Abdelhameed AG
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1373-1380. PubMed ID: 31127381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can subthreshold micropulse yellow laser treatment change the anti-vascular endothelial growth factor algorithm in diabetic macular edema? A randomized clinical trial.
    Kanar HS; Arsan A; Altun A; Akı SF; Hacısalihoglu A
    Indian J Ophthalmol; 2020 Jan; 68(1):145-151. PubMed ID: 31856493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab or Aflibercept for Diabetic Macular Edema: Comparison of 1-Year Outcomes from the Fight Retinal Blindness! Registry.
    Bhandari S; Nguyen V; Fraser-Bell S; Mehta H; Viola F; Baudin F; Gabrielle PH; Creuzot-Garcher C; Gillies M; Barthelmes D
    Ophthalmology; 2020 May; 127(5):608-615. PubMed ID: 31932092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of subthreshold micropulse laser combined with ranibizumab in the treatment of diabetic macular edema.
    Bıçak F; Kayıkçıoğlu ÖR; Altınışık M; Doğruya S; Kurt E
    Int Ophthalmol; 2022 Dec; 42(12):3829-3836. PubMed ID: 35876939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
    Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
    Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subthreshold micropulse laser reduces anti-VEGF injection burden in patients with diabetic macular edema.
    Moisseiev E; Abbassi S; Thinda S; Yoon J; Yiu G; Morse LS
    Eur J Ophthalmol; 2018 Jan; 28(1):68-73. PubMed ID: 28731494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
    Heier JS; Korobelnik JF; Brown DM; Schmidt-Erfurth U; Do DV; Midena E; Boyer DS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Vitti R; Berliner AJ; Zeitz O; Metzig C; Holz FG
    Ophthalmology; 2016 Nov; 123(11):2376-2385. PubMed ID: 27651226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
    Brown DM; Schmidt-Erfurth U; Do DV; Holz FG; Boyer DS; Midena E; Heier JS; Terasaki H; Kaiser PK; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Korobelnik JF
    Ophthalmology; 2015 Oct; 122(10):2044-52. PubMed ID: 26198808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
    Wykoff CC; Le RT; Khurana RN; Brown DM; Ou WC; Wang R; Clark WL; Boyer DS;
    Am J Ophthalmol; 2017 Jan; 173():56-63. PubMed ID: 27702624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
    Bahrami B; Hong T; Schlub TE; Chang AA
    Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.